Extracellular vesicles carry distinct signatures across long COVID, ME/CFS, and fibromyalgia

A preprint from bioRxiv describes an extracellular vesicle approach that separates long COVID from ME/CFS and fibromyalgia using targeted surface marker profiling in plasma. The study focused on disorders that share disabling fatigue, pain, cognitive symptoms, and a difficult diagnostic overlap, then asked whether vesicle cargo and surface phenotype could reflect the biology driving those syndromes rather than just their symptoms.

The premise is clinically intuitive. Extracellular vesicles circulate as membrane-bound messengers released by platelets, immune cells, and endothelium, and their surface markers can mirror the state of the parent cell. In a patient with persistent post-viral symptoms, a vesicle readout that captures platelet activation, antigen presentation, leukocyte trafficking, and renin-angiotensin signaling offers a plausible window into systemic dysregulation that routine labs often miss.

Coordinated changes were strongest in the long COVID group

The investigators analyzed EV-enriched plasma from ME/CFS, fibromyalgia, patients co-diagnosed with ME/CFS and fibromyalgia, long COVID, and matched healthy controls, with 10 participants in each group. EV concentration and size distribution were measured by nanoparticle tracking analysis, followed by AlphaScreen profiling of tetraspanins CD9 and CD63 and a panel of markers linked to platelets, myeloid cells, immune activity, and the renin-angiotensin system.

Long COVID stood out as the most altered group. Plasma from those participants showed increased levels of CD9/CD74, CD9/CX3CR1, and CD9/ACE1-positive EVs together with reduced overall particle concentrations. The pattern points to more than a single isolated pathway. CD74 is tied to antigen presentation and inflammatory signaling, CX3CR1 relates to leukocyte trafficking and vascular interaction, and ACE1 reflects a shift toward pro-inflammatory renin-angiotensin activity. In combination, those signals suggest a synchronized disturbance in immune-endothelial cross talk rather than a narrow biomarker drift.

A single blood compartment was carrying signs of several stressed systems at once.

Platelet activation appeared in both long COVID and ME/CFS

Platelet-derived EVs carried another important clue. CD9/CD41/CD61-positive vesicles were significantly elevated in both long COVID and ME/CFS compared with healthy controls, indicating enhanced platelet activation in those two groups. Platelet activation matters because activated platelets do not only participate in coagulation; they also amplify inflammation, interact with leukocytes, and influence microvascular flow. In disorders marked by post-exertional symptom worsening, exertional intolerance, and dysautonomia-like complaints, a chronic platelet-endothelial signal could help explain why patients describe symptoms that feel vascular, inflammatory, and exertional all at once.

The finding also helps separate the syndromes biologically. Fibromyalgia, despite symptom overlap, did not emerge from the abstract as sharing the same platelet signature to the same degree. This kind of divergence is exactly what a biomarker strategy must prove if it is to move beyond symptom labels and toward a mechanism-based classification.

Immune and vascular markers favored a post-infectious inflammatory pattern

Among the immune-associated markers, CD74-positive EVs in long COVID pointed toward antigen presentation and inflammatory signaling, while CX3CR1-positive EVs suggested altered leukocyte trafficking and vascular interaction. ACE1-positive EVs added a renin-angiotensin signal that leans toward pro-inflammatory tone. Together, these markers fit with a model in which persistent immune activation and endothelial stress continue after the acute infection has resolved.

That biology has direct bedside implications. A patient can appear “medically unexplained” if the evaluation is limited to standard imaging and routine chemistry, yet still harbor measurable endothelial and immune activation at the vesicle level. The study does not claim that vesicle profiling replaces clinical diagnosis, but it does suggest that a plasma-based panel could eventually help separate a post-infectious syndrome from related chronic pain and fatigue disorders that otherwise blur together in clinic.

Diagnostic separation remains the central promise

The value of the work lies in its differential signature, not in a single marker. By integrating platelet, immune, and vascular-associated EV markers, the panel distinguished long COVID from ME/CFS and fibromyalgia in a way that a single symptom score cannot. For clinicians, that is important because these conditions often overlap in presentation while likely diverging in upstream biology. For researchers, the study offers a systems-level framework for testing whether persistent symptoms map to platelet activation, immune signaling, endothelial dysfunction, or a combination of all three.

The sample size was small, with 10 participants per group, so these findings need validation in larger cohorts before any diagnostic role can be considered. The preprint status also matters because the work has not yet undergone peer review. Still, the direction of travel is clear: a vesicle profile that captures platelet activation, antigen presentation, leukocyte trafficking, and ACE1-linked signaling could become a useful biomarker architecture for post-viral syndromes and chronic overlapping pain-fatigue disorders.

For now, the most concrete takeaway is biological rather than therapeutic. Long COVID displayed the most coherent EV disturbance, and platelet activation was shared with ME/CFS, while fibromyalgia did not appear to mirror the same signature to the same extent. Those differences are the first requirement for any future blood test meant to distinguish syndromes that today are often grouped together by symptoms alone.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by bioRxiv (Biomedical Preprints).